Unlock stock picks and a broker-level newsfeed that powers Wall Street. Upgrade Now Frankfurt - Delayed Quote • EUR Leap Therapeutics, Inc. (5MC.F) Follow Compare 0.1380 +0.0560 +(68.29%) As of 8:10:55 AM GMT+2. Market Open. Comparisons Indicators Technicals Corporate Events Draw List View Grid View Detach Attach No Tool Measure UNDO Redo All All Favorites Text Statistics Technicals Fibonacci Markings Lines Annotation Arrow Line Horizontal Vertical Rectangle Trend Line Measurement Line Average Line Callout Channel Check Continuous Crossline Elliott Wave Ellipse Doodle Fib Projection Fib Arc Fib Fan Fib Time Zone Focus Gann Fan Gartley Heart Pitchfork Quadrant Lines Ray Regression Line Fib Retracement Star Speed Resistance Arc Speed Resistance Line Time Cycle Tirone Levels Volume Profile Cross Magnet Clear All Drawings Restore Default Parameters Loading Chart for 5MC.F 1D 5D 1M 3M 6M YTD 1Y 5Y All Date Range 1 min Recent News: 5MC.F View More All News Press Releases SEC Filings Penny Stock Leap Therapeutics Unveils Positive Data From Experimental Combo Therapy For Colorectal Cancer Leap Therapeutics Says New Data Show Sirexatamab Improves Survival in Colorectal Cancer Trial Leap Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results Leap Therapeutics Reports Positive Updated Data from Sirexatamab Colorectal Cancer Study Leap Therapeutics Reports Initial Clinical Data from Part B of the DeFianCe Study and Part C of the DisTinGuish Study Leap Therapeutics to Participate at the 43rd Annual J.P. Morgan Healthcare Conference Leap Therapeutics to Participate at Piper Sandler 36th Annual Healthcare Conference Leap Therapeutics Reports Third Quarter 2024 Financial Results Leap Therapeutics Announces Completion of Enrollment in Part B of the DeFianCe Study of DKN-01 for the Treatment of Colorectal Cancer Patients Leap Therapeutics Reports Second Quarter 2024 Financial Results Leap Therapeutics Inc (LPTX) Q1 2024 Earnings: Financial Resilience Amidst Clinical Progress